Cargando…

An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures

OBJECTIVE: To assess the impact of patient cost-sharing for antihypertensive medications on the proportion of days covered (PDC) by antihypertensive medications, medical utilization, and health care expenditures among commercially insured individuals assigned to different risk categories. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Pesa, Jacqueline A, Van Den Bos, Jill, Gray, Travis, Hartsig, Colleen, McQueen, Robert Brett, Saseen, Joseph J, Nair, Kavita V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269319/
https://www.ncbi.nlm.nih.gov/pubmed/22298945
http://dx.doi.org/10.2147/PPA.S28396
_version_ 1782222457402294272
author Pesa, Jacqueline A
Van Den Bos, Jill
Gray, Travis
Hartsig, Colleen
McQueen, Robert Brett
Saseen, Joseph J
Nair, Kavita V
author_facet Pesa, Jacqueline A
Van Den Bos, Jill
Gray, Travis
Hartsig, Colleen
McQueen, Robert Brett
Saseen, Joseph J
Nair, Kavita V
author_sort Pesa, Jacqueline A
collection PubMed
description OBJECTIVE: To assess the impact of patient cost-sharing for antihypertensive medications on the proportion of days covered (PDC) by antihypertensive medications, medical utilization, and health care expenditures among commercially insured individuals assigned to different risk categories. METHODS: Participants were identified from the Consolidated Health Cost Guidelines (CHCG) database (January 1, 2006–December 31, 2008) based on a diagnosis (index) claim for hypertension, continuous enrollment ≥12 months pre- and post-index, and no prior claims for antihypertensive medications. Participants were assigned to: low-risk group (no comorbidities), high-risk group (1+ selected comorbidities), or very high-risk group (prior hospitalization for 1+ selected comorbidities). The relationship between patient cost sharing and PDC by antihypertensive medications was assessed using standard linear regression models, controlling for risk group membership, and various demographic and clinical factors. The relationship between PDC and health care service utilization was subsequently examined using negative binomial regression models. RESULTS: Of the 28,688 study patients, 66% were low risk. The multivariate regression model supported a relationship between patient cost sharing per 30-day fill and PDC in the following year. For every US$1.00 increase in cost sharing, PDC decreased by 1.1 days (P < 0.0001). Significant predictors of PDC included high risk, older age, gender, Charlson Comorbidity Index score, geography, and total post-index insurer- and patient-paid costs. An increase in PDC was associated with a decrease in all-cause and hypertension-related inpatient, outpatient, and emergency room visits and medical, pharmacy, and total costs. CONCLUSIONS: The trend has been for managed care organizations and employers to require patients to bear a greater out-of-pocket burden for health care resources consumed. This study illustrates the potential adverse effects of higher patient cost sharing among patients with hypertension stratified by different risk levels. A decrease in PDC was predictive of higher resource utilization and health care costs, which should be of interest to payers and employers alike.
format Online
Article
Text
id pubmed-3269319
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32693192012-02-01 An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures Pesa, Jacqueline A Van Den Bos, Jill Gray, Travis Hartsig, Colleen McQueen, Robert Brett Saseen, Joseph J Nair, Kavita V Patient Prefer Adherence Original Research OBJECTIVE: To assess the impact of patient cost-sharing for antihypertensive medications on the proportion of days covered (PDC) by antihypertensive medications, medical utilization, and health care expenditures among commercially insured individuals assigned to different risk categories. METHODS: Participants were identified from the Consolidated Health Cost Guidelines (CHCG) database (January 1, 2006–December 31, 2008) based on a diagnosis (index) claim for hypertension, continuous enrollment ≥12 months pre- and post-index, and no prior claims for antihypertensive medications. Participants were assigned to: low-risk group (no comorbidities), high-risk group (1+ selected comorbidities), or very high-risk group (prior hospitalization for 1+ selected comorbidities). The relationship between patient cost sharing and PDC by antihypertensive medications was assessed using standard linear regression models, controlling for risk group membership, and various demographic and clinical factors. The relationship between PDC and health care service utilization was subsequently examined using negative binomial regression models. RESULTS: Of the 28,688 study patients, 66% were low risk. The multivariate regression model supported a relationship between patient cost sharing per 30-day fill and PDC in the following year. For every US$1.00 increase in cost sharing, PDC decreased by 1.1 days (P < 0.0001). Significant predictors of PDC included high risk, older age, gender, Charlson Comorbidity Index score, geography, and total post-index insurer- and patient-paid costs. An increase in PDC was associated with a decrease in all-cause and hypertension-related inpatient, outpatient, and emergency room visits and medical, pharmacy, and total costs. CONCLUSIONS: The trend has been for managed care organizations and employers to require patients to bear a greater out-of-pocket burden for health care resources consumed. This study illustrates the potential adverse effects of higher patient cost sharing among patients with hypertension stratified by different risk levels. A decrease in PDC was predictive of higher resource utilization and health care costs, which should be of interest to payers and employers alike. Dove Medical Press 2012-01-18 /pmc/articles/PMC3269319/ /pubmed/22298945 http://dx.doi.org/10.2147/PPA.S28396 Text en © 2012 Pesa et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Pesa, Jacqueline A
Van Den Bos, Jill
Gray, Travis
Hartsig, Colleen
McQueen, Robert Brett
Saseen, Joseph J
Nair, Kavita V
An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures
title An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures
title_full An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures
title_fullStr An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures
title_full_unstemmed An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures
title_short An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures
title_sort evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269319/
https://www.ncbi.nlm.nih.gov/pubmed/22298945
http://dx.doi.org/10.2147/PPA.S28396
work_keys_str_mv AT pesajacquelinea anevaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT vandenbosjill anevaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT graytravis anevaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT hartsigcolleen anevaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT mcqueenrobertbrett anevaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT saseenjosephj anevaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT nairkavitav anevaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT pesajacquelinea evaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT vandenbosjill evaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT graytravis evaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT hartsigcolleen evaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT mcqueenrobertbrett evaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT saseenjosephj evaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures
AT nairkavitav evaluationoftheimpactofpatientcostsharingforantihypertensivemedicationsonadherencemedicationandhealthcareutilizationandexpenditures